Why some gene therapies face sluggish launches

[cafead]

via U.S. regulators approved Bluebird Bio’s gene therapy for patients with sickle cell disease, Lyfgenia, last December. Yet eight months into the launch, only four patients have started the $3.1 million one-time treatment for the blood disorder.

article source